• Policy
• Re-evaluation of the upper limit amt, scheduled for August
• by Lee, Tak-Sun Jul 31, 2023 05:27am

• Company
• Erleada can be prescribed at tertiary hospitals in KOR
• by Eo, Yun-Ho Jul 28, 2023 05:30am

• Policy
• Janssen’s MM drug Tecvayli Inj is approved in KOR
• by Lee, Hye-Kyung Jul 28, 2023 05:30am

• InterView
• ‘Leclaza can occupy 50% of mkt if used as combination'
• by Jung, Sae-Im Jul 28, 2023 05:30am

• Policy
• Maintenance of grounds for original drug price
• by Kim, Jung-Ju Jul 27, 2023 05:40am

• Company
• Celltrion applies for approval of its Eylea biosimilar in KR
• by Jung, Sae-Im Jul 27, 2023 05:40am

• Company
• Atozet market, ↑ 225% in 2 years
• by Chon, Seung-Hyun Jul 27, 2023 05:40am

• Company
• Reimb discussions imminent for Obizur in Korea
• by Eo, Yun-Ho Jul 27, 2023 05:40am

• Policy
• NHIS extends Bavencio’s reimb...adds KRW 20 bil sales
• by Lee, Tak-Sun Jul 27, 2023 05:40am

• Company
• Astellas launches urothelial cancer drug Padcev
• by Kim, Jin-Gu Jul 26, 2023 05:41am